Drug shortage in Russia continues to stimulate uncontrolled rise of prices
Prices for a wide range of drugs in the Russian pharmaceutical retail sector are steadily growing due to a significant reduction of their supplies and disappearance from retail shelves.
One of such product is hypoglycemic drug Trulicity (dulaglutide) manufactured by Eli Lilly (NYSE: LLY), used by patients with type 2 diabetes, which has practically disappeared from Moscow pharmacies and prices for which leftovers grew by two- to three times, compared to the maximum selling price of the drug. The same situation is observed with Bristol Myers Squibb’s (NYSE: BMY) anticancer Opdivo (nivolumab), marketed by Swixx Biopharma. Both drugs are included in the list of essential drugs, the cost of which is regulated by the state.
One of the ways to solve the existing problem may involve the increase of supplies of analogues of disappeared drugs, although there are serious interruptions with their supplies to Russia as well.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze